Holen Sie sich die Stockscreener-App
85.38
1.52%
-1.32
Vorhandelsmarkt:
85.69
0.31
+0.36%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$86.70
Offen:
$85.06
24-Stunden-Volumen:
1.82M
Relative Volume:
1.07
Marktkapitalisierung:
$42.23B
Einnahmen:
$9.93B
Nettoeinkommen (Verlust:
$1.12B
KGV:
37.95
EPS:
2.25
Netto-Cashflow:
$1.58B
1W Leistung:
-2.47%
1M Leistung:
-10.43%
6M Leistung:
-3.23%
1J Leistung:
-3.23%
1-Tages-Spanne:
$84.94
$85.72
1-Wochen-Bereich:
$84.94
$87.64
52-Wochen-Spanne:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
85.38 | 43.30B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
552.41 | 196.08B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
173.01 | 49.62B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
244.76 | 36.04B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
80.12 | 15.87B | 3.93B | 415.40M | 384.70M | 2.06 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - Insider Monkey
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
US FDA approves Alcon's new dry-eye drug - Reuters
Alcon up 4% as FDA approves Tryptyr drops for dry eye - Seeking Alpha
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
Trump Says TikTok Agreement Will Not Mirror US Steel Deal - PYMNTS.com
Turkey Contact Lens MarketCompetition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more - Yahoo
U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - GlobeNewswire Inc.
FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar - PYMNTS.com
FTC Probing Alcon's $430M Lensar Deal - Law360
Eye care product makers Alcon, LENSAR get second request from US FTC - MLex
Alcon (ALC) Receives Upgrade to Buy from Kepler Cheuvreux | ALC Stock News - GuruFocus
Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Call Transcript - MSN
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy - GuruFocus
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy | ALC Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Alcon's (VTX:ALC) Profits May Not Reveal Underlying Issues - Yahoo Finance
Alcon (VTX:ALC) Strong Profits May Be Masking Some Underlying Issues - simplywall.st
RBC cuts Alcon stock price target to CHF95, keeps Outperform rating - Investing.com Canada
RBC Capital Adjusts Price Target for Alcon (ALC) While Maintaining Optimism | ALC Stock News - GuruFocus
Stifel maintains Alcon stock Buy rating, $100 target amid new drug launch - Investing.com Nigeria
Deutsche Bank Downgrades Alcon (ALC) Rating, Lowers Price Target | ALC Stock News - GuruFocus
Deutsche Bank cuts Alcon stock rating, lowers price target - Investing.com
Deutsche Bank cuts Alcon stock rating, lowers price target By Investing.com - Investing.com Nigeria
RBC cuts Alcon stock price target to CHF95, keeps Outperform rating By Investing.com - Investing.com South Africa
LENSAR Announces Merger with Alcon Research - TipRanks
Alcon updates 2025 sales growth target to 6%-7% driven by new product launches and tariff mitigation - MSN
Alcon stock target cut to $109 by Bernstein on Q2 outlook - Investing.com Nigeria
Alcon’s Earnings Call: Balancing Growth and Challenges - TipRanks
Alcon (ALC) Sees Notable Increase in Borrow Rate | ALC Stock New - GuruFocus
India Ophthalmic Devices Market Forecast Report 2025-2033, Competitive Analysis of Alcon, Bausch Health, Carl Zeiss, Meditec, Essilor, Hoya, Johnson & Johnson, Nidek, Topcon - Yahoo
Alcon (ALC) Sees Notable Increase in Borrow Rate | ALC Stock News - GuruFocus
Alcon Q1 2025 slides: Revenue guidance raised despite margin pressures from tariffs - Investing.com Canada
Alcon Inc (ALC) Q1 2025 Earnings Call Highlights: Resilient Growth Amid Market Challenges - Yahoo
Alcon Revises Outlook As Swiss Market Stays Steady - Finimize
Alcon First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Alcon Inc. Reports Strong Q1 2025 Earnings Growth - TipRanks
Alcon Earnings: Lukewarm Start to Year Raises Stakes for Back Half of 2025; Tariff Impact Mild - Morningstar
Soft First-Quarter Readout Puts Spotlight on Product Launches and Operational Excellence - Morningstar
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):